The buzz around ibogaine, a plant‑derived drug from West Africa, exploded when a U. S. president highlighted its promise at a White House event that celebrated psychedelic research. For the first time, the Food and Drug Administration has cleared a clinical trial to test the substance in people.
Doctors in the U. S. now have another tool to fight a tough cancer. The FDA gave the green light for early use of an experimental pill called daraxonrasib. It targets pancreatic ductal adenocarcinoma, a fast-spreading form of pancreatic cancer that has already resisted other treatments. Patients who
For decades, drug testing followed the same slow rhythm. Researchers ran trials in stages, then paused for months to analyze data before asking regulators for the next step. Patients waited years for treatments while paperwork piled up. Now, a new FDA approach cuts out the waiting by letting regulat
The Food and Drug Administration is preparing for a new leader at its Center for Biologics Evaluation and Research. Last month the agency announced that Vinay Prasad, who has worked as an oncologist and was vocal about U. S. drug policies, would step down by the end of April. The decision to replace
Peptides are tiny chains of amino acids that some people inject hoping for big results. They’re marketed for faster healing, better skin, stronger muscles, and more energy. Influencers and athletes swear by them, but most peptides lack strong scientific proof. Without clear research, users are essen
The U. S. health watchdog is about to check if some lab-made peptides can be mixed freely in pharmacies. Peptides—tiny protein pieces—are popping up in treatments for everything from sleep troubles to weight loss. Yet most of these mixes skip the usual safety checks. A panel will meet in late July
A wide range of cough drops sold under different brand names has been suddenly pulled from shelves after health officials found problems at a factory in China. The U. S. Food and Drug Administration spotted issues during a routine inspection back in August 2025, but hasn’t explained exactly what wen
The U. S. Food and Drug Administration is preparing to review whether certain peptides—short chains of amino acids often hyped as quick-fix health boosters—should face fewer restrictions. These substances, popular in wellness circles and among some celebrities, have never undergone rigorous testing
The Food and Drug Administration announced a July meeting to review whether six or more unapproved peptide injections should move from a restricted drug category. These small protein fragments, popular with fitness influencers and some celebrities, promise quick muscle gains, injury healing or anti‑
Dog owners in the U. S. might soon have a new tool to help their aging pets live healthier, longer lives. A California-based company is testing a drug called LOY-002, designed to slow down aging in dogs. Unlike typical medications that treat specific diseases like arthritis or cancer, this pill aims
